Troponin Testing and Early MI Discharge
Sixth-generation high-sensitivity cardiac troponin T assay classifies more patients below a low-risk threshold at presentation.
By
Kathryn Wighton
June 1, 2026
Clinical Scorecard: Troponin Testing and Early MI Discharge
At a Glance
Category Detail
Condition Non-ST-segment elevation myocardial infarction (MI) Key Mechanisms High-sensitivity cardiac troponin T concentrations Target Population Adults with suspected non-ST-segment elevation MI Care Setting Secondary and tertiary hospitals
Key Highlights
61% of patients had sixth-generation troponin T concentrations < 13 ng/L at presentation. 8% of patients met the primary outcome of type 1, 4b, or 4c MI or cardiac mortality within 30 days. The sixth-generation assay showed a negative predictive value of 99.9% and sensitivity of 99.4%. 41% of patients identified as low risk using the sixth-generation assay compared to 17% with the fifth-generation assay. The sixth-generation assay reduced the need for serial troponin testing (23% vs 43%). Guideline-Based Recommendations
Diagnosis
Utilize sixth-generation high-sensitivity cardiac troponin T for assessing MI risk. Management
Consider early discharge for low-risk patients identified by the sixth-generation assay. Monitoring & Follow-up
Monitor cardiac troponin T levels as part of MI assessment. Risks
Potential for misclassification of low risk in female patients. Patient & Prescribing Data
Predominantly White adults, median age 59 years, 38% female.
Implementation of the sixth-generation assay may facilitate earlier discharge.
Clinical Best Practices
Validate the sixth-generation assay in diverse cohorts. Conduct prospective studies to confirm findings. Related Resources & Content
